1Guan Y, Zhang Y, Schneider A, et al. Peroxisome proliferator-actirated receptor-gamma activity is associated with renal microvasculature[ J]. Am J Physiol Renal Physiol,2001,281 (6) :F1036.
2Bermudez V, Finol F, Parra N, et al. PPAR-gamma agonists and their role in type 2 diabetes mellitus management [ J ]. Am J Ther,2010,17(3) :274 -283.
3Yu J,Zhang Z, Li Z, et al. Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease [J]. J Int Mcd Res,2010,38(1) :86 -94.
4Zheng F, Fornoni A, Elliot SJ, et al. Upregulation of type Ⅰ collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation [ J]. Am J Physiol Renal Physiol,2002,282 (4) : F639 - F648.
5Zafiriou S, Stanners SR, Saad S, et al. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts [J]. J Am Soc Nephrol,2005,16(3) :638 -645.
6Panchapakesan U, Sumual S, Pollock CA, et al. PPARgamma agonists exert antifibrotic effects in renal tubular cells exposed to high glucose [ J]. Am J Physiol Renal Physiol, 2005,289 ( 5 ) : F1153 - F1158.
7Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents[ J]. J Diabetes Complications,2002,16( 1 ) :123 - 132.
8Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients[ J]. Diabetes,2005,54 (7) :2206 - 2211.
9Arima S, Kohagura K ,Takeuchi K, et al. Biphasic vasodilator action of troglitazone on the renal microcirculation[ J]. J Am Soc Nephrol, 2002,13 (2) :342 -349.
